Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease

 Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease

Nuformix Signs an Exclusive WW License Agreement with Oxilio to Develop NXP001 for Oncology Disease

Shots:

  • Nuformix is eligible to receive an up front, development milestone along with royalties when the net sales reaching $2.76M/annum
  • Oxilio gets an exclusive license to research, develop and commercialize NXP001 globally for oncology indications. The agreement allows Oxilio to focus on developing a unique formulation and dosage form with NXP001 to progress into the clinic
  • NXP001 is a new form of aprepitant which is marketed in the oncology supportive care setting. Additionally, Nuformix has obtained the patents on new forms of NXP001 with improved properties & focuses to develop two lead assets NXP002 and NXP004

Click here to read full press release/ article | Ref: Nuformix | Image: Linkedin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post